quinuclidines has been researched along with Genetic Predisposition in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, RM; Grubbs, J; Huynh, K; Liu, KC | 1 |
| Awada, A; Ghanem, G; Journe, F; Krayem, M; Marine, JC; Morandini, R; Najem, A; Salès, F; Sibille, C; van Kempen, LC; Wiedig, M | 1 |
1 review(s) available for quinuclidines and Genetic Predisposition
| Article | Year |
|---|---|
Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.
Topics: Animals; Antigen-Presenting Cells; Apoptosis; Autoantibodies; Autoimmunity; Cyclosporine; Genetic Predisposition to Disease; Humans; Immunity, Cellular; Immunity, Humoral; Keratoconjunctivitis Sicca; Molecular Mimicry; Quinuclidines; Sjogren's Syndrome; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thiophenes | 2014 |
1 other study(ies) available for quinuclidines and Genetic Predisposition
| Article | Year |
|---|---|
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Predisposition to Disease; Humans; Indoles; Male; Melanoma; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinuclidines; Signal Transduction; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |